Drug Trial Radar · NCT06791291
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5
Actual
Start
Jul 25, 2025
Primary completion
Mar 6, 2028
Study completion Mar 6, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 34 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment. Teplizumab has been approved by FDA to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. The dose regimen of teplizumab in this study is consistent with the regimen approved by US FDA. Given prior clinical studies conducted in Western countries, this design is appropriate to assess the efficacy, safety and tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of a 14-day IV infusion regimen of teplizumab in Japanese Stage 2 T1D participants aged 1 to 34 years.
Conditions
- Type 1 Diabetes Mellitus
Interventions
TeplizumabDrug
Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Stage 3 Type 1 Diabetes based on American Diabetes Association criteriaTime frame: From baseline up to Week 104
- Change from baseline in area under the curve (AUC) of C-peptideTime frame: From baseline up to Week 104
- Change from baseline in AUC of endogenous insulinTime frame: From baseline up to Week 104
- Number of participants with TEAEs, SAEs, AEs leading to permanent study intervention- or study discontinuation; AEs of special interest; number of participants with clinically significant changes in vital signs, ECG, and/or safety laboratory testTime frame: Throughout the study, approximately 756 days
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number : 3920017
Fukuoka, Japan
Investigational Site Number : 3920016
Kyoto, Japan
Investigational Site Number : 3920014
Nagasaki, Japan
Investigational Site Number : 3920004
Osaka, Japan
Investigational Site Number : 3920020
Tokyo, Japan
Investigational Site Number : 3920003
Tokyo, Japan
Investigational Site Number : 3920015
Ichikawa, Chiba, Japan
Investigational Site Number : 3920011
Maebashi, Gunma, Japan
Investigational Site Number : 3920006
Sapporo, Hokkaido, Japan
Investigational Site Number : 3920018
Kobe, Hyōgo, Japan
Investigational Site Number : 3920009
Kanazawa, Ishikawa-ken, Japan
Investigational Site Number : 3920007
Yahaba, Iwate, Japan
Investigational Site Number : 3920019
Yokohama, Kanagawa, Japan
Investigational Site Number : 3920001
Iruma, Saitama, Japan
Investigational Site Number : 3920010
Chūō, Yamanashi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.